Monitor recipients of phosphodiesterase type 5 inhibitors for glaucoma, pending more clinical evidence of risk
Crossref DOI link: https://doi.org/10.1007/s40267-020-00709-x
Published Online: 2020-02-10
Published Print: 2020-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
,
Text and Data Mining valid from 2020-02-10
Version of Record valid from 2020-02-10
Article History
First Online: 10 February 2020
Compliance with ethical standards
:
: The authors declare no conflicts of interest.
: The preparation of this review was not supported by any external funding.